These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8420374)

  • 1. Serum levels of interleukin-2 receptor in ocular Behçet's disease.
    BenEzra D; Maftzir G; Kalichman I; Barak V
    Am J Ophthalmol; 1993 Jan; 115(1):26-30. PubMed ID: 8420374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood serum interleukin-1 receptor antagonist in pars planitis and ocular Behçet disease.
    Benezra D; Maftzir G; Barak V
    Am J Ophthalmol; 1997 May; 123(5):593-8. PubMed ID: 9152064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relation between serum homocysteine level and eye involvement in Behçet's disease.
    Aflaki E; Mehryar M; Nazarinia MA; Habibagahi Z; Rajaee A; Ranjbar-Omrani G
    Arch Iran Med; 2008 Nov; 11(6):625-8. PubMed ID: 18976033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum leptin levels in patients with ocular and nonocular Behçet's disease.
    Yalçindağ FN; Kisa U; Batioğlu F; Yalçindağ A; Ozdemir O; Cağlayan O
    Mediators Inflamm; 2007; 2007():31986. PubMed ID: 17641728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behçet's uveitis.
    Ahn JK; Seo JM; Yu J; Oh FS; Chung H; Yu HG
    Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2458-64. PubMed ID: 15980236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble endothelial protein C receptor levels in Behçet patients with and without ocular involvement.
    Yalçindağ FN; Batioğlu F; Ozdemir O; Cansizoğlu E; Eğin Y; Akar N
    Graefes Arch Clin Exp Ophthalmol; 2008 Nov; 246(11):1603-8. PubMed ID: 18604550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behçet's syndrome: ocular features in an Australian population.
    Wakefield D; McCluskey P
    Aust N Z J Ophthalmol; 1990 May; 18(2):129-35. PubMed ID: 2390239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum prolactin levels in Behçet's disease.
    Apaydin KC; Duranoglu Y; Ozgürel Y; Saka O
    Jpn J Ophthalmol; 2000; 44(4):442-5. PubMed ID: 10974304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could be serum uric acid a risk factor for thrombosis and/or uveitis in Behcet's disease?
    Atıl A; Deniz A
    Vascular; 2018 Aug; 26(4):378-386. PubMed ID: 29360007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term therapy with low dose cyclosporin A in ocular Behçet's disease.
    Ozdal PC; Ortaç S; Taskintuna I; Firat E
    Doc Ophthalmol; 2002 Nov; 105(3):301-12. PubMed ID: 12539855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of regulatory T cells by infliximab in Behcet's disease.
    Sugita S; Yamada Y; Kaneko S; Horie S; Mochizuki M
    Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):476-84. PubMed ID: 20861484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behçet's disease: correlations with disease activity and severity.
    Yosipovitch G; Shohat B; Bshara J; Wysenbeek A; Weinberger A
    Isr J Med Sci; 1995 Jun; 31(6):345-8. PubMed ID: 7607852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ocular manifestations in Behçet's disease].
    Desbois AC; Terrada C; Cacoub P; Bodaghi B; Saadoun D
    Rev Med Interne; 2018 Sep; 39(9):738-745. PubMed ID: 29625716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease.
    Whitcup SM; Salvo EC; Nussenblatt RB
    Am J Ophthalmol; 1994 Jul; 118(1):39-45. PubMed ID: 8023874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating antibodies to inducible heat shock protein 70 in patients with uveitis.
    de Smet MD; Ramadan A
    Ocul Immunol Inflamm; 2001 Jun; 9(2):85-92. PubMed ID: 11449324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bolus of cyclophosphamide and methylprednisolone in uveitis in Behçet's disease. Preliminary results with the use of new criteria of evaluation].
    Hamza M; Meddeb S; Mili I; Ouertani A
    Ann Med Interne (Paris); 1992; 143(7):438-41. PubMed ID: 1300863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
    Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
    Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Berberine exerts an anti-inflammatory role in ocular Behcet's disease.
    Yang Y; Wang Q; Xie M; Liu P; Qi X; Liu X; Li Z
    Mol Med Rep; 2017 Jan; 15(1):97-102. PubMed ID: 27922688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between serum levels of angiogenin, bFGF, VEGF, and ocular involvement in patients with Behçet's disease.
    Yalçındağ A; Gedik-Oğuz Y; Yalçındağ FN
    Graefes Arch Clin Exp Ophthalmol; 2013 Jul; 251(7):1807-12. PubMed ID: 23553285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis.
    Kitaichi N; Kotake S; Sasamoto Y; Namba K; Matsuda A; Ogasawara K; Onoé K; Matsuda H; Nishihira J
    Invest Ophthalmol Vis Sci; 1999 Jan; 40(1):247-50. PubMed ID: 9888451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.